Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2025)

Lyell Immunopharma's Share-based Compensation history spans 6 years, with the latest figure at $5.2 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 31.36% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $24.3 million, down 27.39%, while the annual FY2024 figure was $33.1 million, 29.61% down from the prior year.
  • Share-based Compensation for Q3 2025 was $5.2 million at Lyell Immunopharma, up from $5.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $22.4 million in Q2 2022 and bottomed at $5.0 million in Q2 2025.
  • The 5-year median for Share-based Compensation is $12.7 million (2021), against an average of $12.7 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 73.01% in 2022 before it tumbled 53.91% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $21.2 million in 2021, then decreased by 13.29% to $18.4 million in 2022, then crashed by 53.91% to $8.5 million in 2023, then dropped by 4.49% to $8.1 million in 2024, then crashed by 35.27% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Share-based Compensation are $5.2 million (Q3 2025), $5.0 million (Q2 2025), and $6.0 million (Q1 2025).